Arbutus Biopharma (ABUS) Tops Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Arbutus Biopharma (ABUS) Tops Q1 EPS by 2c

Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 5, 2021 7:30 AM EDT

AB-729, Arbutus proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data

Additional data from the ongoing Phase 1a/1b clinical trial of AB-729, including 60 mg multi-dose data (dosing interval every 4 and 8 weeks) and 90 mg multi-dose data (dosing interval every 8 weeks), expected in 2Q/2021

A proof-of-concept Phase 2 triple combination clinical trial evaluating AB-729, and Assembly Biosciences core inhibitor candidate, vebicorvir (VBR), with an... More